Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

此前，瓯江实验室首席科学家李校堃、资深研究员穆萨·穆罕默迪、特聘研究员陈高帜团队共同在《自然》杂志发表文章《FGF激素信号传导的结构基础》，其研究便是通过冷冻电镜完成。该文章在国际上首次完整展示FGF23、FGFR、Klotho和HS四元复合物分子机 ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) on November 12 and set a ...

Multi-kinase inhibition by fexagratinib may offer a more comprehensive therapeutic approach than selective FGFR inhibition in ...

Tyra Bioscience, Inc ( (TYRA) ) has released its Q3 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its ...

探索罕疾的展览「我的平凡日常，谁的诗与远方：降低30公分，走进罕病『软骨发育不全症』人生」11／12起在南港瓶盖工厂免费展出。展览以动态体验、装置艺术、纪实摄影、文件纪录、影像、生活辅具、行动支持等七大展区，生动且立体的呈现软骨发育不全症患者的生活处 ...

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months.

Allovir Inc., which has struggled since late last December, will merge with privately held Kalaris Therapeutics Inc. to develop therapies for treating neovascular and exudative retinal diseases.

During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...

被称为ecDNA的小圆圈对癌症的发展和耐药性至关重要。一个由斯坦福大学医学院领导的国际团队发表了具有里程碑意义的研究，详细介绍了新的发现和潜在的治疗方法。 斯坦福大学医学研究人员及其国际合作者的三篇研究论文改变了科学家对过往被认为无关紧要的环状小DNA的理解——是许多类型人类癌症的主要驱动因素。